International Liver Cancer Association (ILCA) White Paper on Biomarker Development for
Hepatocellular Carcinoma Page 1 1 International Liver Cancer Association (ILCA) White Paper …

The mainstay for the diagnosis for hepatocellular carcinoma (HCC) includes serological
tumor markers, such as-fetoprotein, the L3 fraction thereof and PIVKA-II, in addition to …

Tumour markers could be helpful along the continuum of care for patients with
hepatocellular carcinoma; however, there is insufficient data for routine use of most current …

Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. The
HCC diagnosis is usually achieved by biomarkers, which can also help in prognosis …

Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths
worldwide. If diagnosed early, curative treatment options such as surgical resection, loco …

Hepatocellular carcinoma (HCC) is the fifth most common cancer and the second leading
cause of cancer-related deaths worldwide. Although the prognosis of patients with HCC is …

New biomarkers of hepatocellular carcinoma (HCC) have been identified using advanced
genomic, proteomic, and metabolomics technologies. These are being developed not only …

Background: The effectiveness of tumor markers in evaluating outcomes of patients with
hepatocellular carcinoma (HCC) remains to be clarified. Summary: The usefulness of the …

Hepatocellular carcinoma (HCC) is one of the most lethal cancers worldwide, representing
also the main cause of death among cirrhotic patients. In contrast to most other solid tumors …

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Cirrhosis
caused by hepatitis B virus, hepatitis C virus or chronic alcohol intake is associated with …